Glucuronidation genotypes and nicotine metabolic phenotypes: Importance of functional UGT2B10 and UGT2B17 polymorphisms

Cancer Research

Volumn 70, Issue 19, 2010, Pages 7543-7552

  Chen, Gang ^a   Giambrone Jr , Nino E ^a   Dluzen, Douglas F ^a   Muscat, Joshua E ^a   Berg, Arthur ^a   Gallagher, Carla J ^a   Lazarus, Philip ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' HYDROXYCOTININE; COTININE; GLUCURONOSYLTRANSFERASE 2B10; GLUCURONOSYLTRANSFERASE 2B17; GLYCOSYLTRANSFERASE; NICOTINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CAUCASIAN; CONTROLLED STUDY; FEMALE; GENE DELETION; GENOTYPE; GLUCURONIDATION; HOMOZYGOSITY; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; URINE LEVEL; WILD TYPE;

ADULT; AGED; FEMALE; GENOTYPE; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MIDDLE AGED; MOUTH MUCOSA; NICOTINE; POLYMORPHISM, GENETIC; SMOKING;

EID: 77957354096     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-4582     Document Type: Article

References (35)

1. Hatsukami DK, Stead LF, Gupta PC. Tobacco addiction. Lancet 2008;371:2027-38.
2. Benowitz NL, Jacob P, 3rd. Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin Pharmacol Ther 1994;56: 483-93.
3. Hukkanen J, Jacob P, 3rd, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev 2005;57:79-115.
4. Caldwell WS, Greene JM, Byrd GD, et al. Characterization of the glucuronide conjugate of cotinine: a previously unidentified major metabolite of nicotine in smokers' urine. Chem Res Toxicol 1992;5: 280-5.
5. Byrd GD, Uhrig MS, deBethizy JD, et al.Direct determination of cotinine- N-glucuronide in urine using thermospray liquid chromatography/mass spectrometry. Biol Mass Spectrom 1994;23:103-7.
6. Byrd GD, Caldwell WS, Bhatti BS, Ravard A, Crooks PA. Determination of nicotine N-1-glucuronide, a quaternary N-glucuronide conjugate, in human biological samples. Drug Metabol Drug Interact 2000; 16:281-97.
7. Ghosheh O, Vashishtha SC, Hawes EM. Formation of the quaternary ammonium-linked glucuronide of nicotine in human liver microsomes: identification and stereoselectivity in the kinetics. Drug Metab Dispos 2001;29:1525-8.
8. Kuehl GE, Murphy SE. N-glucuronidation of trans-3′-hydroxycotinine by human liver microsomes. Chem Res Toxicol 2003;16:1502-6.
9. Chen G, Blevins-Primeau AS, Dellinger RW, Muscat JE, Lazarus P. Glucuronidation of nicotine and cotinine by UGT2B10: loss of function by the UGT2B10 codon 67 (Asp>Tyr) polymorphism. Cancer Res 2007;67:9024-9.
10. Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human phase I metabolizing enzymes except for cytochrome P450 and phase II metabolizing enzymes. Drug Metab Pharmacokinet 2006;21:357-74.
11. Chen G, Dellinger RW, Gallagher CJ, Sun D, Lazarus P. Identification of a prevalent functional missense polymorphism in the UGT2B10 gene and its association with UGT2B10 inactivation against tobacco-specific nitrosamines. Pharmacogenet Genomics 2008;18:181-91.
12. Lazarus P, Zheng Y, Aaron Runkle E, Muscat JE, Wiener D. Genotype-phenotype correlation between the polymorphic UGT2B17 gene deletion and NNAL glucuronidation activities in human liver microsomes. Pharmacogenet Genomics 2005;15:769-78.
13. Gallagher CJ, Muscat JE, Hicks AN, et al. The UDP-glucuronosyltransferase 2B17 gene deletion polymorphism: sex-specific association with urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol glucuronidation phenotype and risk for lung cancer. Cancer Epidemiol Biomarkers Prev 2007;16:823-8.
14. R-project org [homepage on the Internet]. R Development Core Team (2009). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria; ISBN 3-900051-07-0 [update 2009; cited 2010 Mar 26]. Available from: http://www.R-project.org.
15. Broberg P. SAGx: Statistical Analysis of the GeneChip [homepage on the Internet]. R package version 1.20.0; [Cited 2010 Mar 26]. Available from: http://home.swipnet.se/pibroberg/expression-hemsida1.html.
16. Benowitz NL, Jacob P, 3rd, Fong I, Gupta S. Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. J Pharmacol Exp Ther 1994;268:296-303.
17. Murata M, Warren EH, Riddell SR. A human minor histocompatibility antigen resulting from differential expression due to a gene deletion. J Exp Med 2003;197:1279-89.
18. Wilson W 3rd, Pardo-Manuel de Villena F, Lyn-Cook BD, et al. Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15. Genomics 2004;84:707-14.
19. Kuehl GE, Murphy SE. N-glucuronidation of nicotine and cotinine by human liver microsomes and heterologously expressed UDP-glucuronosyltransferases. Drug Metab Dispos 2003;31:1361-8.
20. Kaivosaari S, Toivonen P, Hesse LM, Koskinen M, Court MH, Finel M. Nicotine glucuronidation and the human UDP-glucuronosyltransferase UGT2B10. Mol Pharmacol 2007;72:761-8.
21. Berg JZ, Mason J, Boettcher AJ, Hatsukami DK, Murphy SE. Nicotine metabolism in African Americans and European Americans: variation in glucuronidation by ethnicity and UGT2B10 haplotype. J Pharmacol Exp Ther 2009;332:202-9.
22. Yamanaka H, Nakajima M, Katoh M, et al. Trans-3′-hydroxycotinine O- and N-glucuronidations in human liver microsomes. Drug Metab Dispos 2005;33:23-30.
23. Hecht SS, Carmella SG, Murphy SE. Effects of watercress consumption on urinary metabolites of nicotine in smokers. Cancer Epidemiol Biomarkers Prev 1999;8:907-13.
24. Hecht SS, Hatsukami DK, Bonilla LE, Hochalter JB. Quantitation of 4-oxo-4-(3-pyridyl)butanoic acid and enantiomers of 4-hydroxy-4- 3-pyridyl)butanoic acid in human urine: a substantial pathway of nicotine metabolism. Chem Res Toxicol 1999;12:172-9.
25. Benowitz NL, Jacob P, 3rd. Nicotine and cotinine elimination pharmacokinetics in smokers and nonsmokers. Clin Pharmacol Ther 1993;53:316-23.
26. Malaiyandi V, Sellers EM, Tyndale RF. Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clin Pharmacol Ther 2005;77:145-58.
27. Nakajima M, Yokoi T. Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation. Drug Metab Pharmacokinet 2005;20:227-35.
28. Benowitz NL, Hukkanen J, Jacob P, 3rd. Nicotine chemistry, metabolism, kinetics and biomarkers. Handb Exp Pharmacol 2009: 29-60.
29. Dempsey D, Tutka P, Jacob P, 3rd, et al. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther 2004;76:64-72.
30. Ho MK, Mwenifumbo JC, Zhao B, Gillam EM, Tyndale RF. A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent. Pharmacogenet Genomics 2008;18:67-75.
31. Lerman C, Tyndale R, Patterson F, et al. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin Pharmacol Ther 2006;79:600-8.
32. Patterson F, Schnoll RA, Wileyto EP, et al. Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Clin Pharmacol Ther 2008;84:320-5.
33. Ray R, Tyndale RF, Lerman C. Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes. J Neurogenet 2009;23:252-61.
34. Schnoll RA, Patterson F, Wileyto EP, Tyndale RF, Benowitz N, Lerman C. Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacol Biochem Behav 2009;92:6-11.
35. Ho MK, Mwenifumbo JC, Al Koudsi N, et al. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clin Pharmacol Ther 2009;85:635-43.